SAB Biotherapeutics Inc. (SABS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, SAB Biotherapeutics Inc. (NASDAQ: SABS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.35 (+3.72% 1D, market cap $293.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 4/20. Across 1016 tracked Health Care issuers, SABS ranks #611 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SABS carries a Roarable D- (37/100 RQD), trailing P/E of 22.1x, gross margin of —, and ROIC of -27.4%. By comparison, EIKN (Eikon Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $289.8M) and AGEN (Agenus Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $320.2M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).
Per SABS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833214), SAB Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), $13.3M in net income, and -$45.7M in free cash flow against $172.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 7.07 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.20% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SABS currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.25) and Max Pain ($3.52) forces dealer call-delta covering toward $5.41.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.20% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SAB Biotherapeutics Inc. (SABS) surged +3.72% to $3.35, trading at 34% of its 52-week range ($2.44 – $5.15). Stretched risk/reward at 22x P/E (-27% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and ot
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and ot
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SABS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SABS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SAB Biotherapeutics Inc. (SABS) ranks #611 by composite RQD confidence (37/100, grade D-) and #521 by equity capitalization ($293.9M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. EIKN currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with SABS at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SABS
ACTIVE
SAB Biotherapeutics Inc. | D- | 37/100 | 22.1x | — | -27.4% | +3.72% | $293.9M | Benchmark Subject |
| EIKN Eikon Therapeutics Inc. | D- | 42/100 | — | — | — | -0.75% | $289.8M | /eikn-vs-sabs → |
| AGEN Agenus Inc. | E | 30/100 | — | 96.0% | -35.0% | -3.53% | $320.2M | /agen-vs-sabs → |
| CABA Cabaletta Bio Inc. | E | 33/100 | — | — | -35.0% | -4.73% | $268.7M | /caba-vs-sabs → |
| IPSC Century Therapeutics Inc. | E | 18/100 | — | — | -14.1% | +0.69% | $264.4M | /ipsc-vs-sabs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SAB Biotherapeutics Inc. (SABS) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $1.3M , and -100.0% cumulative change since FY2023) , GAAP net income of $13.3M, operating cash flow of -$44.8M, and free cash flow of -$45.7M (-32.0% YoY). On the balance sheet, SABS closed FY2025 with $172.8M in total assets against $0 in total debt (Altman Z-Score: 7.07, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $13.3M | -$44.8M | -$45.7M | $172.8M | — |
| FY2024 (FY) | 2024-12-31 | $1.3M | -$34.1M | -$34.3M | -$34.6M | $44.2M | — |
| FY2023 (FY) | 2023-12-31 | $2.2M | -$42.2M | -$25.1M | -$25.1M | — | — |
As of 2026-11-02, SAB Biotherapeutics Inc. (NASDAQ: SABS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.35 (+3.72% 1D, market cap $293.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 4/20. Across 1016 tracked Health Care issuers, SABS ranks #611 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SABS carries a Roarable D- (37/100 RQD), trailing P/E of 22.1x, gross margin of —, and ROIC of -27.4%. By comparison, EIKN (Eikon Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $289.8M) and AGEN (Agenus Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $320.2M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).
Per SABS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833214), SAB Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), $13.3M in net income, and -$45.7M in free cash flow against $172.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SABS last traded at $3.35 (+3.72% on volume of 741,056 shares), positioning the stock +3.08% above its 50-day simple moving average ($3.25) and -8.97% below its 200-day simple moving average ($3.68). Across its 52-week range of $2.44 to $5.15, SABS sits at the 33.6% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.93 to $3.77).
Why SABS Stock surged +3.72% Today — RQD Quant Desk Flash. Stretched risk/reward at 22x P/E (-27% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SABS scores 37 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:
Taken together, the rating frames SABS as a company whose balance sheet is comparatively sturdy but whose cash generation and flow indicators are weak. The upside case rests on the balance sheet giving management runway; the valuation tradeoff is that a P/E of 22.1 (TTM) sits against negative ROIC and negative FCF yield, meaning the earnings multiple is not being supported by operating cash returns. Second-order risk is that continued cash burn could erode the balance-sheet strength the forensic pillar currently credits.
SAB Biotherapeutics Inc. (SABS) is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances). Per the company profile, it has a market capitalization of $0.3B. Per the recent news wire, the company's pipeline activity includes SAB-142, which received FDA Fast Track Designation in Type 1 Diabetes. The source data does not describe its customers or detail how it generates revenue, and reported revenue is $0.0M for FY 2025.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-49.0M | $13.3M | N/A | $-45.7M | $10.5M | N/A |
| FY 2024 | $1.3M | $-42.9M | $-34.1M | N/A | $-34.6M | $8.9M | N/A |
| FY 2023 | $2.2M | $-38.1M | $-42.2M | N/A | $-25.1M | N/A | N/A |
Per the SEC financials, operating losses persisted across all three reported years, and operating margin is recorded as 0% in market data. Gross, operating, and net margins are all listed as 0%, and ROIC stands at -27.4%. The FY 2025 net income of $13.3M contrasts with an operating loss of $-49.0M, a divergence the source data does not explain. Per the Roarable RQD rating, the Altman Z-Score is 7.07 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5; reported cash fell from $10.5M (FY 2025) to $8.9M (FY 2024) in the prior year column, and FY 2025 cash is the latest figure shown.
Proprietary signals: Per the Butterfly Supply-Chain Graph, the proprietary signals list is empty.
Real-time company headlines, analyst actions, and sector developments for SAB Biotherapeutics Inc. (SABS) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering SAB Biotherapeutics Inc. (SABS) market action, institutional positioning, and fundamental catalysts.
Welcome to the SABS (SAB Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SABS, but look at what you are paying: 22.1x trailing P/E with tightening sector spreads. Unless SAB Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SABS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $3.23 (52-wk range $2.44 - $5.15), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).